Lactiga is a biotherapeutics company focused on developing innovative biologics aimed at treating and preventing infections, particularly for patients with Primary Immunodeficiency Diseases (PIDD). The company is leveraging the therapeutic potential of human milk to create next-generation anti-infectives, specifically targeting mucosal infections associated with rare immunodeficiencies. Their research emphasizes the development of novel antibodies derived from maternal breast milk, which are designed to bind and neutralize pathogens, thereby improving the quality of life for affected individuals. Lactiga's work is underscored by the granting of multiple patents in the United States, Canada, and Japan, highlighting the novelty and potential impact of their therapeutic approaches.

In addition to their core focus on immunodeficiency-related infections, Lactiga has gained recognition for its contributions to addressing the COVID-19 pandemic. The company has established partnerships, including a notable NIH-funded collaboration with Mount Sinai, to advance its patented biologic, LCTG-001, for COVID-19 treatment. Lactiga's innovative approach has earned them several awards, including the Canada India Foundation’s Healthcare Innovation Award, which acknowledges their application of biotechnology in combating health crises. Through these efforts, Lactiga aims to provide effective treatment options for millions of patients worldwide facing the challenges of immunodeficiency.

United States

Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. We are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including SARS-CoV-2.

Lactiga has earned awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.

Lactiga

Company Details